Nintedanib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Nintedanib?
Summarize this article for a 10 year old
Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.[5]
Clinical data | |
---|---|
Trade names | Vargatef, Ofev |
Other names | BIBF 1120 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615009 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 4.7% |
Protein binding | 97.8% |
Metabolism | Esterases, glucuronidation |
Elimination half-life | 10–15 hrs |
Excretion | 93% via faeces |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI |
|
ChEMBL |
|
PDB ligand | |
ECHA InfoCard | 100.237.441 |
Chemical and physical data | |
Formula | C31H33N5O4 |
Molar mass | 539.636 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
In March 2020, it was approved for use in the United States to treat chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait).[6] It is the first treatment for this group of fibrosing lung diseases that worsen over time that was approved by the U.S. Food and Drug Administration (FDA).[6]
Common side effects include abdominal pain, vomiting, and diarrhea.[7] It is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet derived growth factor receptor.[5]
Ofev was developed by Boehringer Ingelheim. It received U.S. Food and Drug Administration (FDA) approval for use for idiopathic pulmonary fibrosis in 2014 – one of only two drugs available for treating IPF – and numerous studies since have demonstrated its effectiveness in slowing the progressive, terminal lung disease.[8]